Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Torrent Evasive On Cipla Question, But Comfortable With Domestic Acquisitions

Brazil Sales Force Expanded, Indian Firm Reveals

Executive Summary

Torrent management avoided commenting on valuations or whether big-ticket acquisitions are on the cards during a call to discuss fiscal Q2 results, as it faced a volley of questions on the topic following media reports of its interest in acquiring Cipla. Meanwhile, the Brazil business posted handsome gains during the quarter, while the US business shrunk.

You may also be interested in...

Will More Indian Family-Owned Firms Hand Over The Baton To PEs?

Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, an investment banker tells Scrip.

Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent

Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics

A Myrbetriq Battle Is Brewing And Why It Matters

Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts